Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 3
1954 1
1959 1
1960 2
1961 1
1962 1
1963 4
1964 4
1966 3
1967 2
1968 2
1969 2
1970 1
1971 1
1972 1
1973 2
1975 5
1976 3
1977 1
1978 4
1979 1
1980 4
1982 4
1983 1
1985 5
1986 6
1987 6
1988 7
1989 2
1990 5
1991 6
1992 6
1993 2
1994 3
1995 4
1996 2
1997 5
1998 7
1999 3
2000 3
2001 2
2002 5
2003 3
2004 4
2005 5
2006 8
2007 11
2008 16
2009 23
2010 17
2011 14
2012 14
2013 14
2014 18
2015 13
2016 12
2017 8
2018 20
2019 12
2020 26
2021 30
2022 32
2023 24
2024 18
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

441 results

Results by year

Filters applied: . Clear all
Page 1
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum.
Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Wei JT, et al. Among authors: miner m. J Urol. 2025 Jul;214(1):111. doi: 10.1097/JU.0000000000004546. Epub 2025 Jun 9. J Urol. 2025. PMID: 40488244 No abstract available.
Relative Impact of Male Urinary Conditions on Overall Quality of Life.
Vasudevan V, Fernandez GM, Dunn RL, Miner M, Roehrborn C, Rosen R, Seftel A, Spino C, Wei JT, Sarma AV; BPH Registry and Patient Survey Steering Committee. Vasudevan V, et al. Among authors: miner m. Neurourol Urodyn. 2025 Jun 2. doi: 10.1002/nau.70090. Online ahead of print. Neurourol Urodyn. 2025. PMID: 40452415
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.
Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhize NN, Weiner JA, Ackerman ME, McElrath MJ, Pensiero M, Barouch DH, Montefiori D, Tomaras GD, Corey L, Cohen MS, Huang Y, Mahomed S, Siegel M, Kelley CF; HVTN 140/HPTN 101 study team. Seaton KE, et al. Among authors: miner md. Lancet HIV. 2025 Jun;12(6):e405-e415. doi: 10.1016/S2352-3018(25)00012-8. Lancet HIV. 2025. PMID: 40441807 Clinical Trial.
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.
Fisher LH, Lazarus E, Yu C, Moodie Z, Stieh DJ, Yates N, Zhang L, Sawant S, De Rosa SC, Cohen KW, Morris D, Grant S, Randhawa A, Miner MD, Hendriks J, Wegmann F, Gill KM, Laher F, Bekker LG, Gray GE, Corey L, McElrath MJ, Martin T, Gilbert PB, Tomaras G, Walsh SR, Baden LR; HVTN 100, HVTN 117/HPX2004 study teams. Fisher LH, et al. Among authors: miner md. PLOS Glob Public Health. 2025 Apr 11;5(4):e0004250. doi: 10.1371/journal.pgph.0004250. eCollection 2025. PLOS Glob Public Health. 2025. PMID: 40215224 Free PMC article.
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.
Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi NM, Andriesen J, Takalani A, Fisher LH, Kee JJ, Magaret CA, Villaran M, Hural J, Andersen-Nissen E, Ferarri G, Miner MD, Le Roux B, Wilkinson E, Lessells R, de Oliveira T, Odhiambo J, Shah P, Polakowski L, Yacovone M, Samandari T, Chirenje Z, Elyanu PJ, Makhema J, Kamuti E, Nuwagaba-Biribonwoha H, Badal-Faesen S, Brumskine W, Coetzer S, Dawson R, Delany-Moretlwe S, Diacon AH, Fry S, Gill KM, Ebrahim Hoosain ZA, Hosseinipour MC, Inambao M, Innes C, Innes S, Kalonji D, Kasaro M, Kassim P, Kayange N, Kilembe W, Laher F, Malahleha M, Maluleke VL, Mboya G, McHarry K, Mitha E, Mngadi K, Mda P, Moloantoa T, Mutuluuza CK, Naicker N, Naicker V, Nana A, Nanvubya A, Nchabeleng M, Otieno W, Potgieter EL, Potloane D, Punt Z, Said J, Singh Y, Tayob MS, Vahed Y, Wabwire DO, McElrath MJ, Kublin JG, Bekker LG, Gilbert PB, Corey L, Gray GE, Huang Y, Kotze P; CoVPN 3008 Ubuntu Study Team. Garrett N, et al. Among authors: miner md. EClinicalMedicine. 2025 Jan 20;80:103054. doi: 10.1016/j.eclinm.2024.103054. eCollection 2025 Feb. EClinicalMedicine. 2025. PMID: 39902315 Free PMC article.
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Edupuganti S, et al. Among authors: miner md. Lancet HIV. 2025 Jan;12(1):e13-e25. doi: 10.1016/S2352-3018(24)00247-9. Epub 2024 Dec 10. Lancet HIV. 2025. PMID: 39667379 Clinical Trial.
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
Naicker V, Laher F, Bekker LG, Seaton KE, Allen M, De Rosa S, Yates NL, Mkhize NN, Saunders K, Heptinstall J, Malahleha M, Mngadi K, Daniels B, Innes C, Yu C, Modise T, Bekker V, Grunenberg N, Furch B, Miner MD, Phogat S, Diazgranados CA, Gurunathan S, Koutsoukos M, Van Der Meeren O, Roxby AC, Ferrari G, Morris L, Montefiori D, McElrath MJ, Tomaras GD, Moodie Z. Naicker V, et al. Among authors: miner md. PLOS Glob Public Health. 2024 Sep 20;4(9):e0003319. doi: 10.1371/journal.pgph.0003319. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39302924 Free PMC article.
441 results